People who undergo nonmyeloablative stem-cell transplants, or “mini transplants,” for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
The research by Marco Mielcarek, M.D., and colleagues in the Hutchinson Center’s Clinical Research Division appear in the December issue of the journal
Biology of Blood and Marrow Transplantation.
“The main message for referring physicians is that if the patient is a candidate for a nonmyeloablative, or mini, transplant but does not have a suitable related donor, the transplant should not be delayed provided a matched unrelated donor is available,” said Mielcarek, the lead author of the paper.
This is a significant finding because historically, “standard” (myeloablative) stem-cell transplants from unrelated matched donors have been associated with increased risk of non-relapse mortality and decreased overall survival compared to transplants from matched related donors. Only 30 percent of patients with hematologic malignancies who might benefit from a stem-cell transplant have a matched related donor.
The combination of immunosuppressive drugs and the unique biology of the mini transplant may be the reasons behind the research results, Mielcarek said.
The Hutchinson Center’s pioneering development 10 years ago of the mini transplant, a kinder, gentler treatment that doesn’t require the intensive radiation and chemotherapy associated with standard stem-cell transplants, made the therapy available to thousands of older patients who were medically unable to withstand the rigors of traditional transplantation.
Such transplants do not require a patient's marrow be destroyed with high-dose radiation and chemotherapy prior to the infusion of donor cells. The technique involves minimal radiation and substantially reduced side effects. The procedure often can be performed in an outpatient clinic.
Mielcarek and colleagues conducted a retrospective study of 221 patients who had matched related donors and 184 patients who had matched unrelated donors. All of the patients underwent mini transplants at the Hutchinson Center between December 1997 and June 2006. After adjusting for confounding factors such as comorbidities, relapse risk, patient age, stem-cell source, preparative regimen, and sex mismatch of donor and recipient, researchers found no statistically significant differences between patients who received unrelated and related matched donor cells in terms of rates of non-relapse mortality, relapse-related or overall mortality. Additionally, overall rates of severe acute and extensive chronic graft-versus-host disease between the two groups were not significantly different.
The preparative regimen for and the immunobiology of nonmyeloablative transplantation may account for the similar outcomes, according to the study. Patients who undergo mini transplants receive potent pre- and post-transplant immunosuppression drugs. This allows a major reduction in pre-transplant chemotherapy without compromising engraftment of the donor cells.
The research paper, “Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors” by Mielcarek and colleagues is available at the journal’s Web site,
http://www.bbmt.org/current .
Source: Fred Hutchinson Cancer Research Center
Related stories:
Radical reform is needed to stop the 'inhumane' practice of transplant tourism
The UK government must bring in presumed consent to organ donation or allow a controlled donor compensation programme for unrelated live donors, in order to bring the "inhumane" practice of transplant tourism from the UK to an end, claims a doctor in this week's
BMJ.
New Organic Catalyst Should Improve Drug Development, Lower Costs
(PhysOrg.com) -- Chemists at Oregon State University have developed a new “organocatalyst” that will play a major role in new drug development, greatly reducing costs while making the process more efficient, effective and environmentally friendly.
What to do with leftover embryos in fertility clinics?
The majority of infertility patients are in favor of using left-over embryos for stem cell research and would also support selling left-over embryos to other couples, according to a recent survey.
New laboratory technique improves success in 'highly sensitized' kidney transplants
Kidney transplant specialists at Cedars-Sinai Medical Center have developed innovative laboratory techniques to improve opportunities and success rates for kidney transplant candidates who are at high risk of organ rejection because of previous exposure to donor antigens, according to an article in the Sept. 27 issue of the journal
Transplantation.
Rodent studies suggest mother's diet can affect genes and offspring's risk of allergic asthma
A pregnant mouse's diet can induce epigenetic changes that increase the risk her offspring will develop allergic asthma, according to researchers at National Jewish Health and Duke University Medical Center. Pregnant mice that consumed diets high in supplements containing methyl-donors, such as folic acid, had offspring with more severe allergic airway disease than offspring from mice that consumed diets low in methyl-containing foods. The results of the study are being published Sept. 18, 2008, in the online version of the
Journal of Clinical Investigation and will appear in the October print issue.
Embryonic stem cells might help reduce transplantation rejection
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs.
Living donor liver transplants may drastically decrease mortality from liver failure
Patients with acute liver failure (ALF) could be saved by a transplant from a living donor (LDLT), according to a new study in the September issue of
Liver Transplantation, a journal by John Wiley & Sons. The recent experience of U.S. patients shows that recipient mortality rates and donor morbidity rates are acceptable.
Battling diabetes with beta cells
Affecting eight percent of America's population, diabetes can lead to blindness, kidney failure, strokes and heart disease. Thanks to Tel Aviv University researchers, a new cure –– based on advances in cell therapy –– may be within reach.